Molecular Biosafety

Akinc A. , Zumbuehl A. , Goldberg M. , Leshchiner E. , Busini N. & Hossain N. (2008). A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nature Biotechnology, 26(5), 561–569.

Aliyari R. , & Ding S. (2009). RNA-based viral immunity initiated by the Dicer family of host immune receptors. Immunology Review, 227(1), 176–188.

Behlke M. (2006). Progress towards in vivo use of siRNAs. Molecular Therapeutics, 13(4), 644–670.

Boudreau R. , Martins I. , & Davidson B. (2009). Artificial microRNAs as siRNA shuttles: Improved safety as compared to shRNAs in vitro and in vivo. Molecular Therapeutics, 17(1), 169–175.

Fish J. , & Srivastava D. (2009). MicroRNAs: Opening a new vein in angiogenesis research. Science Signaling, 2(52), pe1. [DOI: 10.1126/scisignal.252pe1]

Frieden M. , & Orum H. (2006). The application of locked nucleic acids in the treatment of cancer. IDrugs, 9(10), 706–711.

Gramantieri L. , Fornari F. , Callegari E. , Sabbioni S. , Lanza G. & Croce C. (2008). MicroRNA involvement in hepatocellular carcinoma. Journal of Cellular and Molecular Medicine, 12(6A), 2189–2204.

He S. , Yang Z. , Skogerbo G. , Ren F. , Cui H. & Zhao H. (2008). The properties and functions of virus encoded microRNA, siRNA, and other small noncoding RNAs. Critical Review of Microbiology, 34(3–4), 175–188.

Hermeking H. (2007). p53 enters the microRNA world. Cancer Cell, 12(5), 414–418.

Jackson A. , Bartz S. , Schelter J. , Kobayashi S. , Burchard J. & Mao M. (2003). Expression profiling reveals off-target gene regulation by RNAi. Nature Biotechnology, 21, 635–637.

Jackson A. , Burchard J. , Leake D. , Reynolds A. , Schelter J. & Guo J. (2006). Position-specific chemical modification of siRNAs reduces “off-target” transcript silencing. RNA, 12(7), 1197–1205.

Judge A. , & MacLachlan I. (2008). Overcoming the innate immune response to small interfering RNA. Human Gene Therapy, 19(2), 111–124.

Klattenhoff C. , & Theurkauf W. (2008). Biogenesis and germ-line functions of piRNAs. Development, 135(1), 3–9.

Landen C. Jr. , Chavez-Reyes A. , Bucana C. , Schmandt R. , Deavers M. & Lopez-Berestein G. (2005). Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Research, 65, 6910–6918.

Layzer J. , McCaffrey A. , Tanner A. , Huang A. , Kay M. , & Sullenger B. (2004). In vivo activity of nuclease-resistant siRNAs. RNA, 10, 766–771.

Lewis R. (2008). MicroRNAs: Commercial products on the horizon. Insight Pharma Reports, Available at: www.insightpharmareports.com/reports_report.aspx?r=557&id=73120

Li C. , Parker A. , Menocal E. , Xiang S. , Borodyansky L. , & Fruehauf J. (2006). Delivery of RNA interference. Cell Cycle, 5(18), 2103–2109.

Lin X. , Ruan X. , Anderson M. , McDowell J. , Kroeger P. & Fesik S. (2005). siRNA-mediated off-target gene silencing triggered by a 7 nt complementation. Nucleic Acids Research, 33(14), 4527–4535.

Marquez R. , & McCaffrey A. (2008). Advances in microRNAs: Implications for gene therapists. Human Gene Therapy, 19(1), 27–38.

Nair V. (2008). Retrovirus-induced oncogenesis and safety of retroviral vectors. Current Opinion in Molecular Therapeutics, 10(5), 431–438.

Oulas A. , Reezko M. , & Poirazi P. (2009). MicroRNAs and cancer–The search begins. IEEE Transactions on Information Technology in Biomedicine, 13(1), 67–77.

Park J. , Nadeau P. , Zucali J. , Johnson C. , & Mergia A. (2005). Inhibition of simian immunodeficiency virus by foamy virus vectors expressing siRNAs. Virology, 343(2), 275–282.

Perron M. , & Provost P. (2008). Protein interactions and complexes in human microRNA biogenesis and function. Frontiers in Bioscience, 13, 2537–2547.

Persengiev S. , Zhu X. , & Green M. (2004). Nonspecific, concentration-dependent stimulation and repression of mammalian gene expression by small interfering RNAs (siRNAs). RNA, 10, 12–18.

Pushparaj P. , Aarthi J. , Manikandan J. , & Kumar S. (2008). siRNA, miRNA, and shRNA: In vivo applications. Journal of Dental Research, 87(11), 992–1003.

Scacheri P. , Rozenblatt-Rosen O. , Caplen N. , Wolfsberg T. , Umayam L. & Lee J. (2004). Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells. Proceedings of the National Academy of Science USA, 101, 1892–1897.

Schiffelers R. , Ansari A. , Xu J. , Zhou Q. , Tang Q. & Storm G. (2004). Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Research, 32, e149.

Tang Q. , Li B. , Woodle M. , & Lu P. (2008). Application of siRNA against SARS in the rhesus macaque model. Methods in Molecular Biology, 442, 139–158.

Tong A. , Zhang Y. , & Nemunaitis J. (2005). Small interfering RNA for experimental cancer therapy. Current Opinions in Molecular Therapeutics, 7(2), 114–124.

Wu L. , & Belasco J. (2008). Let me count the ways: Mechanisms of gene regulation by miRNAs and siRNAs. Molecular Cell, 29(1), 1–7.

Ying S. , Chang D. , & Lin S. (2008). The microRNA (miRNA): Overview of the RNA genes that modulate gene function. Molecular Biotechnology, 38(3), 257–268.

Zhang Y. , Boado R. , & Pardridge W. (2003). In vivo knockdown of gene expression in brain cancer with intravenous RNAi in adult rats. The Journal of Gene Medicine, 5, 1039–1045.

Zhang B. , Pan X. , Cobb G. , & Anderson T. (2007). microRNAs as oncogenes and tumor suppressors. Developmental Biology, 302(1), 1–12.